Pomalidomide plus Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010)

被引：0
|
作者：
Weisel, Katja [1 ]
Dimopoulos, Meletios A. [2 ]
Cavo, Michele [3 ]
Ocio, Enrique M. [4 ]
Palumbo, Antonio [5 ]
Corradini, Paolo [6 ]
Delforge, Michel [7 ]
Oriol, Albert [8 ]
Goldschmidt, Harmut [9 ]
Conticello, Concetta [10 ]
Vacca, Angelo [11 ]
Hansson, Markus [12 ]
Miller, Neil [13 ]
Peluso, Teresa [13 ]
Sternas, Lars [14 ]
Zaki, Mohamed H. [14 ]
Moreau, Philippe [15 ]
机构：
[1] Univ Tubingen Hosp, Tubingen, Germany
[2] Univ Athens, Sch Med, GR-11527 Athens, Greece
[3] Univ Bologna, Sch Med, Bologna, Italy
[4] Hosp Univ Salamanca IBSAL, Salamanca, Spain
[5] Univ Turin, Myeloma Unit, Div Hematol, Turin, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[7] Univ Hosp Leuven, Leuven, Belgium
[8] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[9] Univ Clin Heidelberg, Heidelberg, Germany
[10] Univ Catania, Sch Med, Catania, Italy
[11] Univ Bari, Sch Med, Bari, Italy
[12] Lund Univ, Skane Univ Hosp, Lund, Sweden
[13] Celgene Corp, Boudry, Switzerland
[14] Celgene Corp, Summit, NJ USA
[15] Univ Hosp Nantes, Nantes, France
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] A PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: THE MM-011 TRIAL
    Hagiwara, S.
    Okamoto, S.
    Matsue, K.
    Iida, S.
    Sunami, K.
    Komeno, T.
    Suzuki, K.
    Ando, K.
    Taniwaki, M.
    Tobinai, K.
    Chou, T.
    Kaneko, H.
    Iwasaki, H.
    Uemura, C.
    Tamakoshi, H.
    Zaki, M. H.
    Doerr, T.
    Kuroda, Y.
    Ichinohe, T.
    HAEMATOLOGICA, 2016, 101 : 790 - 790
  • [42] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
    Bahlis, Nizar J.
    Sutherland, Heather
    White, Darrell
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Venner, Christopher P.
    Gasparetto, Cristina
    Del Col, Aldo
    Neri, Paola
    Reece, Donna
    Kauffman, Michael
    Shacham, Sharon
    Unger, T. J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    Chen, Christine
    BLOOD, 2018, 132 (24) : 2546 - 2554
  • [43] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
    San Miguel, Jesus
    Weisel, Katja
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Oriol, Albert
    Alegre, Adrian
    Chen, Christine
    Cavo, Michele
    Garderet, Laurent
    Ivanova, Valentina
    Martinez-Lopez, Joaquin
    Belch, Andrew
    Palumbo, Antonio
    Schey, Stephen
    Sonneveld, Pieter
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed
    Dimopoulos, Meletios
    LANCET ONCOLOGY, 2013, 14 (11): : 1055 - 1066
  • [44] Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)
    Moreau, Philippe
    Weisel, Katja C.
    Song, Kevin W.
    Gibson, Craig J.
    Saunders, Owain
    Sternas, Lars Axel
    Hong, Kevin
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    LEUKEMIA & LYMPHOMA, 2016, 57 (12) : 2839 - 2847
  • [45] MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Hofmeister, Craig C.
    Siegel, David
    Lonial, Sagar
    Laubach, Jacob P.
    Efebera, Yvonne A.
    Vesole, David H.
    Nooka, Ajay K.
    Rosenblatt, Jacalyn
    Raje, Noopur
    Zaki, Mohamed H.
    Hua, Ye
    Li, Yan
    Shah, Sheetal
    Wang, Jianming
    Anderson, Kenneth C.
    BLOOD, 2013, 122 (21)
  • [46] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI)
    Weisel, Katja C.
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Rocafiguera, Albert Oriol
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    San-Miguel, Jesus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] MM-005: A PHASE 1 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
    Richardson, P.
    Hofmeister, C.
    Siegel, D.
    Lonial, S.
    Laubach, J.
    Efebera, Y.
    Vesole, D.
    Nooka, A.
    Rosenblatt, J.
    Raje, N.
    Zaki, M.
    Hua, Y.
    Shah, S.
    Wang, J.
    Anderson, K.
    HAEMATOLOGICA, 2013, 98 : 97 - 98
  • [48] ANALYSIS OF MM-003 PATIENTS WITH MODERATE RENAL IMPAIRMENT USING POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Weisel, K.
    Dimopoulos, M.
    Moreau, P.
    Lacy, M.
    Song, K.
    Delforge, M.
    Karlin, L.
    Goldschmidt, H.
    Banos, A.
    Oriol, A.
    Alegre, A.
    Chen, C.
    Cavo, M.
    Garderet, L.
    Ivanova, V.
    Martinez-Lopez, J.
    Yu, X.
    Sternas, L.
    Jacques, C.
    Zaki, M.
    San Miguel, J.
    HAEMATOLOGICA, 2013, 98 : 105 - 105
  • [49] MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM)
    Richardson, Paul Gerard Guy
    Hofmeister, Craig C.
    Siegel, David Samuel DiCapua
    Lonial, Sagar
    Laubach, Jacob
    Efebera, Yvonne Adeduni
    Vesole, David H.
    Nooka, Ajay K.
    Rosenblatt, Jacalyn
    Raje, Noopur S.
    Zaki, Mohamed H.
    Hua, Ye
    Shah, Sheetal
    Wang, Jianming
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Weisel, K.
    Song, K. W.
    Delforge, M.
    Karlin, L.
    Goldschmidt, H.
    Moreau, P.
    Banos, A.
    Oriol, A.
    Garderet, L.
    Cavo, M.
    Ivanova, V.
    Alegre, A.
    Martinez-Lopez, J.
    Chen, C. I.
    Spencer, A.
    Knop, S.
    Bahlis, N. J.
    Renner, C.
    Yu, X.
    Hong, K.
    Sternas, L.
    Jacques, C.
    Zaki, M. H.
    San Miguel, J. F.
    HAEMATOLOGICA, 2014, 99 : 365 - 365
12345